Chelsea Therapeutics' experimental rheumatoid arthritis drug trial gets FDA nod - Small Cap Network

As we told our readers last Friday, Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) was set to run higher in anticipation of FDA news. This morning, the company has announced that the U.S. Food and ...

Arbitration to begin over disputed arthritis drug - WINKNEWS.com

WHITEHOUSE STATION, N.J. (AP) - Drugmaker Merck & Co. says arbitration will begin in late September in its dispute with Johnson & Johnson over revenue from two blockbuster drugs for rheumatoid arthritis ...

Merck, J&J arbitration on drug rights starts soon - msnbc.com

Drugmaker Merck & Co. said Tuesday that arbitration will begin in late September in its dispute with Johnson & Johnson over revenue from two blockbuster drugs for rheumatoid arthritis and other immune disorders.The ...

Bristol-Myers to Buy Partner on Hepatitis Drug for $885 Million - BusinessWeek

arthritis, melanoma and multiple sclerosis. It markets Recothrom, a drug to control bleeding in surgery, which generated net sales of $11.9 million in the second quarter, the company said in a filing. ZymoGenetics ...

Scientists identify molecular gatekeeper of arthritis - Genetic Engineering News

... arthritis in mice, scientists report in a study published in the Journal of Experimental ... including testing whether drug compounds that alter the expression or activity of Gαq in mice can slow the ...

Rodent of the Week: Can having rheumatoid arthritis protect against Alzheimer's disease? - Los Angeles Times

... arthritis is present in the body may reduce the risk of Alzheimer's disease ... is already approved by the Food and Drug Administration for treating certain cancer patients. "Our study, along with the drug's ...

Botox Maker Busy Testing Drug Overseas - CBS News

While drug maker Allergan has pled guilty to illegally marketing its drug Botox for unapproved uses such ... arthritis and curvature of the penis according to records at clinicaltrials.gov. Allergan is recruiting ...

MorphoSys Initiates Program Against Drug-Resistant MRSA Infections - msnbc.com

MorphoSys AG / MorphoSys Initiates Program Against Drug-Resistant MRSA Infections processed and ... is currently tested in a Phase Ib/IIa trial in rheumatoid arthritis patients. Via its business unit AbD Serotec,

Merck: Arbitration with Johnson & Johnson over arthritis drugs' revenue to start ... - Washington Examiner

... blockbuster drugs for rheumatoid arthritis and other immune disorders. The dispute arose when Merck bought Schering-Plough Corp., which has shared billions in revenue with J&J from Remicade and a successor drug,

Roche Cancer Drug Hits Roadblock - Yahoo Finance

PK - News ) recently announced that the US Food and Drug Administration (FDA) refused to accept ... discontinuation of development of ocrelizumab for rheumatoid arthritis due to an unfavorable risk-benefit profile ...